The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials.
Vinu Madhusudanannair
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Hazem Edmond El-Osta
No relevant relationships to disclose
Rajyalakshmi Luthra
No relevant relationships to disclose
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose